New developments in metastatic breast cancer to be reported at ASCO 2012 meeting in Chicago
May 21st, 2012 by Ellen Shnidman
Biotechnology pioneer company Genentech is moving ahead with its latest advance in the treatment of metastatic breast cancer. Data from its newest therapy, TDM-1, will be showcased at the premier annual cancer meeting in America called ASCO (American Society for Clinical Oncology) on June 1-5, 2012 in Chicago.
Data is being presented from the pivotal clinical trial called EMILIA, which includes women with a particularly aggressive type of breast cancer that expresses the HER2 protein on its tumor cells. These women have already been treated with chemotherapy and another Genentech targeted therapy called Herceptin. While this combination has extended the lives of many women with metastatic breast cancer, invariably they become resistant to this regimen after a period of time, and the tumor starts growing again and can’t be stopped, leading to eventual death.
In the EMILIA trial, women who were resistant to their previous treatment combination responded to Genentech’s new drug TDM-1 taken alone, and lived longer than a comparable group of women taking an alternative combination therapy regimen.
TDM-1, therefore, may represent another breakthrough in prolonging the life of women with metastatic breast cancer, by giving them another option, after their first therapy regimen has failed.
According to a member of breast cancer support group, HER2support.org, women are already calling Genentech to get access to TDM-1, even before it is officially approved by the FDA.